Mezigdomide

Last updated
Mezigdomide
Mezigdomide.svg
Legal status
Legal status
  • Investigational
Identifiers
  • 4-{4-[(4-{[2-((3S)-2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-4-yl]oxymethyl}phenyl)methyl]piperazin-1-yl}-3-fluorobenzonitrile
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
Formula C32H30FN5O4
Molar mass 567.621 g·mol−1
3D model (JSmol)
  • N#Cc1ccc(N2CCN(Cc3ccc(COc4cccc5c4CN([C@H]4CCC(=O)NC4=O)C5=O)cc3)CC2)c(F)c1
  • InChI=1S/C32H30FN5O4/c33-26-16-23(17-34)8-9-27(26)37-14-12-36(13-15-37)18-21-4-6-22(7-5-21)20-42-29-3-1-2-24-25(29)19-38(32(24)41)28-10-11-30(39)35-31(28)40/h1-9,16,28H,10-15,18-20H2,(H,35,39,40)/t28-/m0/s1
  • Key:YTINZZFBHWSAGL-NDEPHWFRSA-N

Mezigdomide is a cereblon E3 ligase modulator developed by Bristol Myers Squibb to treat multiple myeloma. [1] [2] [3] [4] [5]

References

  1. ↑ Richardson, Paul G.; Trudel, Suzanne; Quach, Hang; Popat, Rakesh; Lonial, Sagar; Orlowski, Robert Z.; Kim, Kihyun; Mateos, María-Victoria; Pawlyn, Charlotte; Ramasamy, Karthik; Martinez-Lopez, Joaquín; Spirli, Alessia; Casas-Avilés, Ignacio; Gong, Jing; Amatangelo, Michael; Katz, Jessica; Maciag, Paulo; Peluso, Teresa; Bahlis, Nizar J. (15 November 2022). "Mezigdomide (CC-92480), a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD), Combined with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Dose-Expansion Phase of the CC-92480-MM-001 Trial". Blood. 140 (Supplement 1): 1366–1368. doi: 10.1182/blood-2022-157945 .
  2. ↑ Gaffney, Bonny; Shi, Yu; de Jong, Petrus; Sanchez, Manuel; Fontanillo, Celia; Lopez-Girona, Antonia; Boss, Isaac W.; Kurtova, Antonina; Carrancio, Soraya; Wong, Lilly; Pierce, Daniel W. (15 November 2022). "Mezigdomide (CC-92480), a Novel Cereblon E3 Ligase Modulator, Induces Vulnerability of Multiple Myeloma Cells to T-Cell-Mediated Killing". Blood. 140 (Supplement 1): 7108–7109. doi: 10.1182/blood-2022-157939 .
  3. ↑ Richardson, Paul G.; Trudel, Suzanne; Popat, Rakesh; Mateos, María-Victoria; Vangsted, Annette J.; Ramasamy, Karthik; Martinez-Lopez, Joaquín; Quach, Hang; Orlowski, Robert Z.; Arnao, Mario; Lonial, Sagar; Karanes, Chatchada; Pawlyn, Charlotte; Kim, Kihyun; Oriol, Albert; Berdeja, Jesus G.; Rodríguez Otero, Paula; Casas-Avilés, Ignacio; Spirli, Alessia; Poon, Jennifer; Li, Shaoyi; Gong, Jing; Wong, Lilly; Lamba, Manisha; Pierce, Daniel W.; Amatangelo, Michael; Peluso, Teresa; Maciag, Paulo; Katz, Jessica; Pourdehnad, Michael; Bahlis, Nizar J. (14 September 2023). "Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma". New England Journal of Medicine. 389 (11): 1009–1022. doi:10.1056/NEJMoa2303194. PMID   37646702. S2CID   261336795.
  4. ↑ Midha, Shonali; Hartley-Brown, Monique A.; Mo, Clifton C.; Hossain, Shahrier; Nadeem, Omar; O'Donnell, Elizabeth K.; Bianchi, Giada; Sperling, Adam S.; Laubach, Jacob P.; Richardson, Paul G. (2 November 2023). "A safety review of recently approved and emerging drugs for patients with relapsed or refractory multiple myeloma". Expert Opinion on Drug Safety. 22 (11): 1049–1071. doi:10.1080/14740338.2023.2274420. PMID   37906232. S2CID   264672983.
  5. ↑ Richardson, Paul G; Mateos, María-Victoria; Vangsted, Annette J; Ramasamy, Karthik; Abildgaard, Niels; Ho, P Joy; Quach, Hang; Bahlis, Nizar J (3 June 2022). "The role of E3 ubiquitin ligase in multiple myeloma: potential for cereblon E3 ligase modulators in the treatment of relapsed/refractory disease". Expert Review of Proteomics. 19 (4–6): 235–246. doi:10.1080/14789450.2022.2142564. PMID   36342226. S2CID   253382728.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.